Statistics from Altmetric.com
Question In patients newly diagnosed with Alzheimer's disease (AD), what effect do different apolipoprotein E (APOE) genotypes have on the rate of cognitive decline?
Inception cohort followed up for 1–6 years (mean 2.47 y).
Health maintenance organisation in Seattle, Washington, USA.
201 patients who were diagnosed with AD within the previous year based on National Institute of Neurological and Cognitive Disorders and Stroke-Alzheimer's Disease and Related Disorders Association and DSM-III-R criteria. Patients with other central nervous system conditions or major psychiatric disorders were excluded.
Assessment of prognostic factors
Patients were grouped according to their APOE genotype: ε2/3 (n=14), ε3/3 (n=75), ε3/4 (n=82), and ε4/4 (n=30).
Main outcome measure
Annual rate of cognitive decline assessed by the Dementia Rating Scale (DRS) total scores …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.